TAVI in ≥90 year old patients: as beneficial as in younger patients

Original Title: Should Transcatheter Aortic valve replacement Be Performed in Nonagenarians? Insights from the STS/ACC TVT Registry. Reference: Mani Arsalan et al. J Am Coll Cardiol. 2016 Mar 29;67(12):1387-95.

Courtesy of Dr. Carlos Fava

The benefit of the transcatheter aortic valve replacement (TAVI) has already been shown in the general population undergoing this procedure. The number of patients over 90 is growing and there is little information available on whether they too will benefit from TAVI at the same extent younger patients do.

The study analyzed TAVI outcomes of 3773 patients ≥90 and 20252 patients <90 at 30 days and 1 year.
Mean age in the first group was 92, and 82 in the second. In the ≥90 group, there were more women, less non cardiac vascular surgery, and less stroke and prior infarction, but there was higher risk of surgical death (STS PROM 9.2% vs. 6.3%; p<0.001).

At in-hospital evolution, the ≥90 group presented more stroke, vascular complications, bleeding, transfusions, more days in intensive care and more death (6.5% vs. 4.5% p<0.001).

At 30 days and one year, there were no differences in stroke, reintervention or AMI rates. Rehospitalization for heart failure was more frequent among nonagenarians at 30 days, but at one year it was the same in both groups.

Mortality was higher among ≥90, (30 days 8.8% vs. 5.9%; p<0.001 and at one year 24.8% vs. 22%; p<0.001, absolute risk 2.8%, relative risk 12.7%).

There were also 15 ≥100 year old patients; not one of them died at 30 days and mortality at one year was 6.7%.
After adjusting by demographic variables, patients ≥90 continued to show a higher rate of heart failure at 30 days and a higher rate of death at 30 days and one year.

Quality of life in this group was lower at 30 days but similar at 12 months, compared to younger patients.

Conclusion
In the daily practice, around 16% of patients undergoing TAVI are ≥90. Even though mortality at 30 days and one year is higher compared mortality in younger patients, absolute and relative differences were modest. TAVI improves quality of life in this group, as well as in younger patients. These data support the safety and efficacy of TAVI in very elderly patients.

Editorial Comment
This is the largest analyzis on the evolution of this age group; it shows that TAVI in nonagenarians not only is feasible and safe, but also improves quality of life to the same degree as in younger patients.

Courtesy of Dr. Carlos Fava
Interventional Cardiologist
Favaloro Foundation – Buenos Aires

More articles by this author

TAVR in Small Annuli: What Valve Should We Use?

One of the major challenges of severe aortic stenosis are patients with small aortic annuli, defined as ≤430 mm² aortic valve area. This condition...

ACC 2025 | TAVI in Low-Risk Patients: 5-Year Outcomes of EVOLUTE LOW RISK

Transcatheter aortic valve implantation (TAVI) is a valid alternative to surgery in low-risk patients with severe aortic stenosis. However, one of its main limitations...

ACC 2025 | BHF PROTECT-TAVI: Are Cerebral Protection Systems Necessary in TAVI?

TAVI has seen a steady increase in use, though stroke continues to be one of its unwanted complications, mostly ischemic and, less frequently, hemorrhagic. The...

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

SMART-CHOICE 3 | Efficacy and Safety of Clopidogrel vs Aspirin Monotherapy in High Risk Patients after Percutaneous Coronary Intervention

Courtesy of Dr. Juan Manuel Pérez. After post percutaneous coronary intervention (PCI) standard duration dual antiplatelet therapy (DAPT), the optimal long term monotherapy strategy is...

RACE Trial: Effect of Balloon Pulmonary Angioplasty and Riociguat on Right Ventricular Afterload and Function in Chronic Thromboembolic Pulmonary Hypertension

Even though pulmonary endarterectomy is the treatment of choice for chronic thromboembolic pulmonary hypertension (CTEPH), up to 40% of patients are not candidates because...

iFR- vs. FFR-Guided Coronary Revascularization: 5-Year Clinical Outcomes

The assessment of coronary stenosis using coronary physiology has become a key tool in guiding revascularization. The two most widely used techniques are fractional...